[Primary Breast Diffuse Large B Cell Lymphoma: Summarization of 12 Cases].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital, Nanjing 210029, Jiangsu Province, China. E-mail: lijianyonglm@ medmail.com.cn.

Published: April 2016

Objective: To investigate the clinicopathological manifestation, immunophenotypic features and prognostic factors of patients with primary breast DLBCL (PB-DLBCL).

Methods: Twelve cases of PB-DLBCL, diagnosed according to the 2008 World Health Organization classification of tumors of hematopoietic and lymphoid tissues, were retrospectively studied.

Results: Most patients were admitted to hospital because of painless unilateral breast mass. Out of 12 cases, 5 were in Ann Arbor stage I (41.7%), 7 case were in stage II (58.3%). Most (89.9%) were assigned to non-GCB subtypes, 11.1% were classified as GCB subtype. The patients who recepted treatment were sensitive to chemotherapy and they were all alive following 12 to 92 months.

Conclusion: Primary breast DLBCL is extremely rare without specific clinical features. They all respond well to chemotherapy and show good prognosis.

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2016.02.027DOI Listing

Publication Analysis

Top Keywords

primary breast
8
breast dlbcl
8
[primary breast
4
breast diffuse
4
diffuse large
4
large cell
4
cell lymphoma
4
lymphoma summarization
4
summarization cases]
4
cases] objective
4

Similar Publications

In the primary analysis of the open-label phase III PRECIOUS study, pertuzumab retreatment combined with trastuzumab plus chemotherapy of physician's choice (PTC) significantly improved investigator-assessed progression-free survival (PFS) compared with trastuzumab plus physician's choice chemotherapy (TC) in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/mBC). Here, we report final overall survival (OS) at the median follow-up of 25.8 months.

View Article and Find Full Text PDF

Objective: To clarify the screening behavior and influencing factors of females with breast cancer and cervical cancer in suburban areas and to provide a scientific basis for the subsequent implementation of targeted health education, intervention measures and the formulation of relevant policies.

Methods: This study used a multi-stage stratified random sampling method to select 4, 000 women in urban and rural areas of Beijing to analyze their behavior, basic situation, and influencing factors regarding cervical and breast cancer screening.

Results: The sample size of the final included valid analysis was 3861 people, and the screening rate was 27.

View Article and Find Full Text PDF

This study aimed to assess the efficacy and safety of three dosing regimens of JMT103 in patients with bone metastases from solid tumors. Eligible patients were randomly assigned to receive JMT103 subcutaneously, 120 mg every 4 weeks (Cohort 1), 120 mg every 8 weeks (Cohort 2), or 180 mg every 8 weeks (Cohort 3) for up to 49 weeks. The primary endpoint was change from baseline to Week 13 in creatinine-adjusted urinary N-telopeptide (uNTx/Cr).

View Article and Find Full Text PDF

Patients with mental illnesses adhere to organized cancer screening programs less frequently than the general population. This systematic review aims to examine the literature to identify studies that evaluate interventions designed to increase cancer screening adherence in people with mental disorders. The review protocol was registered (CRD42024510431) and Pubmed and Scopus were searched up to January 2024.

View Article and Find Full Text PDF

Structural maintenance of chromosome-1A (SMC1A) is overexpressed in various malignancies including triple-negative breast cancer (TNBC). As a core component of the cohesin complex, SMC1A was initially recognized for its involvement in chromosomal cohesion and DNA-repair pathways. However, recent studies have unveiled its pivotal role in epithelial-mesenchymal transition (EMT), metastasis, and chemo- and radio-resistance in cancer cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!